EcoDrugPlus

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSOMYG00000044504
Gene Symbol: CACNG6A
1 Cross references
175 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSOMYG00000042272
Gene Symbol: CACNG6A
1 Cross references
176 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSOMYG00000044498
Gene Symbol: CACNG7A
1 Cross references
179 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSOMYG00000042278
Gene Symbol: CACNG7A
1 Cross references
180 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSOMYG00000044502
Gene Symbol: CACNG8A
1 Cross references
160 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSOMYG00000061259
Gene Symbol: CACNG8A
1 Cross references
161 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSOMYG00000023217
Gene Symbol: CACNA2D1
1 Cross references
220 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSOMYG00000009128
Gene Symbol: CACNA2D1
1 Cross references
219 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSOMYG00000064137
Gene Symbol: CACNA2D3
1 Cross references
217 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSOMYG00000069014
Gene Symbol: CACNA2D4
1 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSOMYG00000020040
Gene Symbol: CACNB2
2 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSOMYG00000067142
Gene Symbol: CACNG4
1 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).